PBAC's latest decision on Abiraterone acetate: Recommended with restriction (2017). Considered for Treatment of metastatic castration-resistant carcinoma of the prostate in combination with a corticosteroid.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-neutral
no incremental cost
Submissions
3
first 2014
Submissions
3
2014 → 2017
Eligible population
Patients with metastatic castration-resistant prostate cancer who have failed or are unsuitable for docetaxel treatment, with WHO performance status of 2 or less, and not previously treated with enzalutamide (or intolerant).
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
Cost-minimisation
Economic model
Cost-minimisation
ICER note
Minor submission; no economic comparison presented.
Submission history
Jul 2014: Not recommended · Authority Required
Mar 2017: Recommended with restriction · Authority Required
Jul 2017: Recommended with restriction · Authority Required